Review and evaluation of 6-hydroxy-dopamine (6-HD): chemical sympathectomy for the treatment of glaucoma.
D000086:Acetazolamide / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists; D000661:Amphetamine; D002924:Ciliary Body; D004106:Dilatation; D004837:Epinephrine / Q000008:administration & dosage / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D005901:Glaucoma / Q000628:therapy*; D006801:Humans; D006892:Hydroxydopamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply; D009638:Norepinephrine; D010636:Phenols; D010862:Pilocarpine / Q000627:therapeutic use; D011680:Pupil; D013562:Sympathectomy; D013997:Time Factors
D000316:Adrenergic alpha-Agonists; D006892:Hydroxydopamines; D010636:Phenols; D010862:Pilocarpine; D000661:Amphetamine; D000086:Acetazolamide; D009638:Norepinephrine; D004837:Epinephrine